The American pharmaceutical company Pfizer announced on March 14 that it would continue to supply medicines to Russia, but the profits from them would be directed to humanitarian aid to Ukrainians.
The company also refuses to conduct new clinical trials in Russia and planned investments in organizing its own production in the country.
“Cutting off the supply of medicines <…> would result in significant suffering and potential death for patients, especially children and the elderly. However, the continued supply of medicines to Russia does not mean that we will continue to do business in Russia as usual. Today we announce that from now on, Pfizer will donate all profits of its Russian division to projects providing direct humanitarian support to the people of Ukraine. site companies.
On March 9, it became known that the Ministry of Industry and Trade of Russia, together with the Ministry of Transport, is actively working to solve logistical problems that have arisen in all industries, putting pharmaceutical products as a priority.
On March 8, Russian Prime Minister Mikhail Mishustin signed a decree on a temporary ban on the export of medical devices from the country supplied by countries that have joined the anti-Russian sanctions. It was noted that this decision will prevent a shortage of medical devices in the country due to restrictive measures imposed by unfriendly states.
Western sanctions were imposed after Russia launched an operation to protect civilians in the Donbass on February 24. A few days earlier, the situation in the region escalated significantly due to shelling by the Ukrainian military. The authorities of the Donetsk and Luhansk republics announced the evacuation of residents to the Russian Federation, and also turned to Moscow for help. On February 21, Russian President Vladimir Putin signed a decree recognizing the independence of the DNR and LNR.
For more up-to-date videos and details about the situation in Donbass, watch the Izvestia TV channel.
#Pfizer #promised #continue #deliveries #medicines #Russia